SSKN Strata Skin Sciences

STRATA Skin Sciences to Report Second Quarter 2023 Financial Results on August 9, 2023

STRATA Skin Sciences to Report Second Quarter 2023 Financial Results on August 9, 2023

HORSHAM, Pa., July 28, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced that it plans to release its second quarter 2023 financial results on Wednesday, August 9, 2023. Management will hold a conference call to review the financial results and provide a corporate update starting at 4:30 PM ET on the same day.

Wednesday, August 9, 2023, 4:30 PM ET

Domestic: 877-269-7756

International: 201-689-7817

Conference ID: 13739272

Webcast:

After the live webcast, the event will be archived for future reference on the STRATA Skin Sciences website at under the investor relations section.

About STRATA Skin Sciences, Inc.

STRATA Skin Sciences is a medical technology company dedicated to developing, commercializing and marketing innovative products for the in-office treatment of various dermatologic conditions such as psoriasis, vitiligo, and acne. Its products include the XTRAC® excimer laser, VTRAC® lamp systems, and the TheraClear®X Acne Therapy System.

STRATA is proud to offer these exciting technologies in the U.S. through its unique Partnership Program. STRATA’s popular partnership approach includes a fee per treatment cost structure versus an equipment purchase, installation and use of the device, on-site training for practice personnel, service and maintenance of the equipment, dedicated account and customer service associates, and co-op advertising support to help raise awareness and promote the program within the practice.

Investor Contact:

Rich Cockrell

CG Capital

Phone: +1 (404) 736-3838

 



EN
28/07/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Strata Skin Sciences

 PRESS RELEASE

STRATA Skin Sciences Announces Closing of $2.42 Million Registered Dir...

STRATA Skin Sciences Announces Closing of $2.42 Million Registered Direct Offering HORSHAM, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (Nasdaq: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced the closing of its previously announced registered direct offering for the issuance and sale of 1,097,547 shares of the Company’s common stock at a per share purchase price of $2.204. Ladenburg Thalmann & Co. Inc. acted as e...

 PRESS RELEASE

STRATA Skin Sciences’ Elevate 360 Consulting Offering Drives Growth in...

STRATA Skin Sciences’ Elevate 360 Consulting Offering Drives Growth in Partner Clinic Operations and Fuels New Partnership Agreements Consulting program optimizes partner clinic businesses with implementation of best practices initiatives, including marketing, reimbursement, and patient retention HORSHAM, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces growth in busi...

 PRESS RELEASE

STRATA Skin Sciences Announces Pricing of $2.42 Million Registered Dir...

STRATA Skin Sciences Announces Pricing of $2.42 Million Registered Direct Offering of Common Stock Priced At-Market Under Nasdaq Rules HORSHAM, Pa., Sept. 03, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced that it has entered into definitive securities purchase agreements with certain institutional investors for the purchase and sale of 1,097,547 shares of the Company’s common...

 PRESS RELEASE

STRATA Skin Sciences to Present at the H.C. Wainwright 27th Annual Glo...

STRATA Skin Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference HORSHAM, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that Dr. Dolev Rafaeli, President and CEO of Strata Skin Sciences will present a corporate overview at the H.C. Wainwright 27th Annual Global Investment Conference. The conference is being held on September 8 – 10, 202...

 PRESS RELEASE

STRATA Skin Sciences IP Portfolio Holds Exclusivity in Combination The...

STRATA Skin Sciences IP Portfolio Holds Exclusivity in Combination Therapies of Its XTRAC Excimer Laser with JAK Inhibitors, Systemic and Biologic Drugs, Bolstering Expansion into New Indications Like Vitiligo and Other Auto-Immune Skin Conditions Strata continues to work closely with CMS to ensure a rapid implementation of the extended codes HORSHAM, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of de...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch